头孢哌酮舒巴坦钠在院内感染应用的成本效果分析

The cost-effectiveness analysis of cefoperazone sulbactam for treating nosocomial infections

目的探讨头孢哌酮舒巴坦钠在院内感染应用的成本效果。方法院内感染住院患者90例根据治疗药物的不同分为A组、B组与C组各30例,A组采用头孢哌酮舒巴坦钠治疗,B组采用头孢唑啉钠治疗,C组采用头孢地嗪钠治疗。结果 A组有效率为90.0%,B组有效率为70.0%,C组的有效率为100.0%,三组有效率对比差异有统计学意义(P<0.05)。三组的医疗成本对比差异有统计学意义(P<0.05)。A组的C/E值为26.80,B组为39.95,C组为35.22,C/E值对比差异有统计学意义(P<0.05)。结论头孢哌酮舒巴坦钠在院内感染治疗中的应用费用少,有效率高,从而有很好的成本效果。

Objective To discuss the cost-effectiveness of cefoperazone sulbactam for treating nosocomial infections. Methods 90 cases of nosocomial infection in hospitalized patients under treatment were equally divided into group A, B and C group of 30 cases, A group were given with cefoperazone sulbactam treatment, B group were given with cefazolin treatment, C group were given with cefodizime treatment. Results The effective rate of the A group was 90.0%, B group was 70.0%, C group was 100.0% and compared among the three groups had statistically difference （P〈0.05）. The medical costs compared among the three groups were had statistically difference（P〈0.05）. A group of C/E valus was 26.80, B group was 39.95, C group was 35.22 that compared the difference had statistically significantly difference （P 〈 0.05）. Conclusion Cefoperazone sulbactam sodium in the treatment of nosocomial infections has costs less and high efficiency, and thus has better cost-effectiveness.